艾昆纬-通过改进的数据和分析方法确保企业卓越（英）

White PaperEnsuring Enterprise Excellence Through an Evolved Approach to Data and Analytics TYSON KUEHL, Principal, IQVIA Consulting VALERIE ENG, Assoc. Principal, IQVIA Consulting PATRICK GORMAN, Manager, IQVIA ConsultingTable of contentsIntroduction 1Improving the use of data and tools to drive impact 1Understanding your own data maturity 3What are the pillars of an evolved data strategy? 4Customer spotlight 8Closing note 10How IQVIA can help you 11About the authors 12References 14 iqvia.com | 1Despite the promise of Big Data and Advanced Analytics, life sciences organizations frequently remain challenged by fundamental business questions. These challenges are, in part, owed to continually evolving socioeconomic, scientific, and technological factors, or misapplication of these new approaches. While these are not new developments, life sciences organizations still struggle with transforming data into actionable insights to achieve commercial excellence. The frequent reason for this is a lack of a holistic strategy that is grounded in use cases that an organization wishes to address. This white paper offers recommendations for tangible actions that organizations should prioritize to turn this data strategy and management challenge into a differentiation opportunity.Improving the use of data and tools to drive impact Healthcare data is at the center of every life sciences organization. It provides insights on patients, providers, and other stakeholders, while ultimately driving business priorities and operations. Life sciences organizations devote teams and invest resources to procuring, managing, and analyzing data. The life sciences analytics industry was estimated to be $26.2B in 2023 and is forecast to grow to $48.4B by 2028, representing a 13.5% CAGR.1 Furthermore, application of new technologies within life sciences analytics is expected to grow at an even faster clip of 25.2% CAGR, reaching $8.88B in 2029.2While the appetite for innovative data approaches is there, Pharma is still challenged with feeding that appetite in an effective and efficient manner. Thus, the industry requires an evolved Data and Analytics Strategy 2.0. The inflection point that the industry faces is a shift from standard data procurement to clear demonstration of return on investment (ROI) and data value maximization. This involves thinking about existing data through new approaches and solutions to meet changing business priorities.One pharmaceutical company that has been at the forefront of using data as a differentiator is Novartis. Since taking over the leadership reins in 2018, Novartis CEO Vas Narasimhan has made a future-focused data strategy a key pillar of the corporate strategy. This has paid off considerably with most recent net sales +10% and core operating income +18% for FY2024.3Introduction2 | Ensuring Enterprise Excellence Through an Evolved Approach to Data and AnalyticsEconomic, societal, scientific, and regulatory changes have complicated da